Pan-Cancer Molecular Biomarkers
Author:
- 29 May 2024
- journal article
- research article
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 44 (2) , 325-337
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? NoAnnals of Oncology, 2020
- The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physiciansAnnals of Oncology, 2020
- The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancerGenes, Chromosomes and Cancer, 2019
- A Tumor-Agnostic NTRK (TRK) InhibitorCell, 2019
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerCancer Cell, 2018
- Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate TumorsThe American Journal of Human Genetics, 2016
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalJAMA Internal Medicine, 2015
- Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trialsDrug Discovery Today, 2015
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR InhibitorsCell Reports, 2014
- Mutational Processes Molding the Genomes of 21 Breast CancersCell, 2012